Biological PsychiatryGeneticsPeer-reviewed journal article
Genetic risk underlying psychiatric and cognitive symptoms in Huntington’s Disease
Natalie Ellis, Amelia Tee, Branduff McAllisteriD, Thomas H. MasseyiD, Duncan James McLauchlaniD, Timothy Stone, Kevin CorreiaiD, Jacob M. LoupeiD, Kyung‐Hee KimiD, Douglas Barker, Eun Pyo HongiD, Michael J. Chao, Jeffrey D. LongiD, Diane E. LucenteiD, Jean Paul Vonsattel, Ricardo Mouro PintoiD, Kawther Abu Elneel, Eliana Marisa RamosiD, Jayalakshmi Srinidhi Mysore, Tammy GillisiD, Vanessa Chantal WheeleriD, Christopher Medway, Lynsey S. HalliD, Seung KwakiD, Cristina SampaioiD, , Peter HolmansiD
Abstract
Huntingtons disease (HD) is an inherited neurodegenerative disorder caused by an expanded CAG repeat in the HTT gene. It is diagnosed following a standardized exam of motor control and often presents with cognitive decline and psychiatric symptoms. Recent studies have detected genetic loci modifying the age at onset of motor symptoms in HD, but genetic factors influencing cognitive and psychiatric presentations are unknown. We tested the hypothesis that psychiatric and cognitive symptoms in HD are influenced by the same common genetic variation as in the general population by constructing polygenic risk scores from large genome-wide association studies of psychiatric and neurodegenerative disorders, and of intelligence, and testing for correlation with the presence of psychiatric and cognitive symptoms in a large sample (n=5160) of HD patients. Polygenic risk score for major depression was associated specifically with increased risk of depression in HD, as was schizophrenia risk score with psychosis and irritability. Cognitive impairment and apathy were associated with reduced polygenic risk score for intelligence. In general, polygenic risk scores for psychiatric disorders, particularly depression and schizophrenia, are associated with increased risk of the corresponding psychiatric symptoms in HD, suggesting a common genetic liability. However, the genetic liability to cognitive impairment and apathy appears to be distinct from other psychiatric symptoms in HD. No associations were observed between HD symptoms and risk scores for other neurodegenerative disorders. These data provide a rationale for treatments effective in depression and schizophrenia to be used to treat depression and psychotic symptoms in HD.
- organism: human
- assay: whole-genome sequencing
- research focus: GWAS / association mapping
- approach: statistical model
- Citations
- 46
- FWCI
- 2.51
- Field percentile
- top 10%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The timing and impact of psychiatric, cognitive and motor abnormalities in Huntington's disease
Branduff McAllister, James F. Gusella, … on behalf of the REGISTRY Investigators of the European Huntington's Disease Network·NeurologyPeer-reviewed·Mar 25, 2021
- Huntingtin CAG repeat size variations outside the Huntington's disease complex: associations with depression and anxiety phenotypes and basal ganglia structure
Magdalena Vater, Nicolas Rost, … Elisabeth B. Binder·bioRxiv·May 22, 2024
- Rare loss-of-function variants in POLD1, PMS1 and FAN1 modify age at onset of motor symptoms in Huntington's disease
Sahar Gelfman, Rujin Wang, … Giovanni Coppola·medRxiv·Jun 22, 2026
- Dissection of Major Depressive Disorder using polygenic risk scores for Schizophrenia in two independent cohort.
Heather C Whalley, Mark J Adams, … Andrew M McIntosh·Translational PsychiatryPeer-reviewed·Nov 1, 2016
- Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease
Galen E.B. Wright, Nicholas S. Caron, … Michael R. Hayden·Human Molecular GeneticsPeer-reviewed·Aug 12, 2020
- Huntingtin CAG repeat is a continuous modifier of brain structure and health vulnerability
Harriet Cullen, Christopher Clarkson, … Arianna Tucci·medRxiv·May 12, 2026